Description_x000D_ General description_x000D_ Parkin RBR E3 ubiquitin protein ligase (PARK2) is a putative tumor suppressor gene. It possesses an amino-terminal region containing the Ubl (ubiquitin like) domain and a carboxy-terminal region with four zinc coordinating domains, that is, RING0, RING1, in between ring (IBR) and RING2. Parkin is a 465 amino acid protein which is part of the ubiquitin-proteasome system that targets proteins for degradation. The gene encoding it is localized on human chromosome 6q25.2-q27._x000D_ Immunogen_x000D_ synthetic peptide CI(298)KELHHFRILGEEQYN(313), corresponding to amino acid residues 298-313 from human parkin. The sequence is completely conserved between human, mouse, and rat._x000D_ Application_x000D_ Anti-Parkin antibody produced in rabbit has been used in Western blotting and immunohistochemistry._x000D_ Physical form_x000D_ Solution of 100 μg (1 mg/mL) in phosphate buffered saline containing 1.0 mg/mL BSA and 0.05% sodium azide._x000D_ Disclaimer_x000D_ Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals._x000D_ Biochem/physiol Actions_x000D_ The expression of parkin RBR E3 ubiquitin protein ligase has been found to be altered in various malignancies. Mutations in the gene encoding it have been linked to autosomal recessive juvenile Parkinson (ARJP) disease. Parkin has a neuroprotective E3 ligase activity and polyubiquitylates proteins before degradation.